Funding for this research was provided by:
Biomedicum Helsinki-säätiö
Finska Läkaresällskapet
Jane ja Aatos Erkon Säätiö
Sigrid Juséliuksen Säätiö
Helsingin Yliopisto
Article History
Received: 2 April 2020
Accepted: 17 June 2020
First Online: 29 June 2020
Ethics approval and consent to participate
: Not applicable
: Not applicable
: OH and AH are shareholders in TILT Biotherapeutics Ltd. JMS and AH are employees of TILT Biotherapeutics Ltd, and TILT-123 is a product of this company. AH and OH are also shareholders in Targovax ASA, and ONCOS-102 is a product of this company.